ArticleNeuro-oncology2025

Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models.

Jessica B Foster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.